Little Green Pharma : Company Update Presentation

ersonal use only

Company Update

ASX:LGP

3 June 2022

Our vision is to reimagine cannabis medicines and do extraordinary things for our patients.

Our purpose is to solve real patient problems.

A world of difference

Disclaimer

Disclaimer

This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) ("LGP") and its activities current as at the date of this presentation. The information in this

onlypresentation is of general background and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in LGP or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) ("Corporations Act").

It should be read in conjunction with LGP's other periodic and continuous disclosure a ouncements filed with the Australian Securities Exchange, which are available at www.asx.com.au.

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire LGP's shares or other securities. This document does not constitute or contain an offer,

useinvitation, solicitation or recommendation with respect to the purchase or sale of any security in LGP.

No liability

The information contained in this document has been prepared in good faith by LGP, however no guarantee representation or warranty expressed or implied is or will be made by any person (including LGP and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this

document.

ersonalTo the maximum extent permitted by law, LGP and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability,

including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the

i formation, statements, opinions, forecasts, reports or other matters, express or implied, c ntained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise tated and the information in this document remains subject to change without notice.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product.

An investment in LGP is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

Forward looking statements

Certain information in this document refers to the intentions of LGP, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause LGP's actual results, performance or achievements to differ from those referred to in this document. Accordingly, LGP and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Past performance is no guarantee of future performance.

This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to LGP's business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words 'likely', 'estimate', 'project', 'intend', 'forecast', 'anticipate', 'believe', 'expect', 'may', 'aim', 'should', 'potential' and similar expressions, as they relate to LGP and its management, are intended to identify forward- looking statements. Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of LGP to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

Acceptance

By accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.

2

Corporate Overview

Capital Structure

Register Breakdown6

Current Share Price1 onlyShares Outstanding1

Options and Performance Rights on Issue Market Capitalisation (undiluted)1

Cash Reserves (31 March 2022) Enterprise Value2

useShareholder

HANCOCK PROSPECTING PTY LTD3

$0.365

240,266,771			Institutional
12,940,536			37%
	Others
~$87.7 million	49%
~$20.1 million
			Board
~$67.6 million			14%

Substantial Shareholders

ShareholdingOwnership

26.7m11.1%

	ELIXXER LTD4	24.7m	10.3%
ersonal		20.3m
	MS FLETA JENNIFER SOLOMON	8.4%
	TIGA TRADING PTY LTD5	16.2m	6.7%
	Top 20 shareholders	134.1m	55.8%
	Board ownership	32.6m	13.6%
1.	As at 1June 2022
2.	Calculated using net cash of $20.1m
3.	Includes associated parties. Holding as advised to market on 6 July 2021
4.	Holding as advised to market on 1 December 2021
5.	Includes associated parties. Holding as advised to market on 2 July 2021
6.	As at 1 February 2022

3

Investment Highlights

LGP represents a market-leading, European and Oceania-focused medicinal cannabis offering for investors seeking exposure to European and Oceania market opportunities

onlyMarket leader in Australia and Denmark

World class cannabis cultivation and manufacturing facilities

useDominant and rapidly expanding EU distribution platform

ersonalStrong growth in sales and patient numbers

Focus on cost management

• First company in Australia to both produce and export cannabis medicines
• First company in Denmark to produce and register locally grown cannabis medicines
• Strong market share in both countries with original, trusted brand that defines LGP
• Two world class production facilities strategically located to service the Southern and Northern hemisphere markets
• Total biomass cultivation capacity of >35 tonnes p.a.
• Both facilities producing EU-GMP recognised cannabis medicines
• Multiple large supply agreements demonstrate market confidence in product quality and facility capacity
• First mover advantage in major European markets with significant capacity to meet growing demand
• Leading EU distribution platform with supply pathways into Denmark, Germany, UK, France, Italy, Poland, and Portugal providing access to over 65% of EU and UK citizens
• Previously-announcedsupply agreements into Europe and UK with potential value of up to $35 million over 3 years following flower development and subject to customer meeting minimum exclusivity purchase and take or pay commitments
• Success in recent Italian flower tender and progression of drug registrations in Portugal and Poland
• Track record of sales growth in Australia and offshore markets
• Revenue increased 50% from FY21 (12-month period) to FY22 (9-month period) to $10.52m
• Record new prescribers and new patient numbers compared to comparative reporting period
• Focus on prudent cost management to drive margin growth
• Clear pathway to increasing margins through cost reduction initiatives whilst increasing utilisation and biomass capacity

4

ersonal use only

Business Model